GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeOne Medicines Ltd (SHSE:688235) » Definitions » YoY Rev. per Sh. Growth

BeOne Medicines (SHSE:688235) YoY Rev. per Sh. Growth : 40.35% (As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is BeOne Medicines YoY Rev. per Sh. Growth?

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months. BeOne Medicines's YoY Rev. per Sh. Growth for the quarter that ended in Mar. 2025 was 40.35%.

BeOne Medicines's Revenue per Share for the three months ended in Mar. 2025 was ¥5.60.


BeOne Medicines YoY Rev. per Sh. Growth Historical Data

The historical data trend for BeOne Medicines's YoY Rev. per Sh. Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeOne Medicines YoY Rev. per Sh. Growth Chart

BeOne Medicines Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
YoY Rev. per Sh. Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -51.62 233.75 18.55 75.70 56.67

BeOne Medicines Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
YoY Rev. per Sh. Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 75.21 58.04 25.53 76.28 40.35

BeOne Medicines YoY Rev. per Sh. Growth Calculation

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months.

BeOne Medicines's YoY Rev. per Sh. Growth for the fiscal year that ended in Dec. 2024 is calculated as:

YoY Rev. per Sh. Growth (A: Dec. 2024 )
=(Revenue per Share (A: Dec. 2024 )-Revenue per Share (A: Dec. 2023 ))/ | Revenue per Share (A: Dec. 2023 ) |
=(20.268-12.937)/ | 12.937 |
=56.67 %

BeOne Medicines's YoY Rev. per Sh. Growth for the quarter that ended in Mar. 2025 is calculated as:

YoY Rev. per Sh. Growth (Q: Mar. 2025 )
=(Revenue per Share (Q: Mar. 2025 )-Revenue per Share (Q: Mar. 2024 )) / | Revenue per Share (Q: Mar. 2024 )) |
=(5.604-3.993)/ | 3.993 |
=40.35 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BeOne Medicines YoY Rev. per Sh. Growth Related Terms

Thank you for viewing the detailed overview of BeOne Medicines's YoY Rev. per Sh. Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


BeOne Medicines Business Description

Address
c/o BeOne Medicines I GmbH, Aeschengraben 27, 21st Floor, Basel, CHE, 4051
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.

BeOne Medicines Headlines

No Headlines